Cullen/Frost Bankers’s Inovio Pharmaceuticals INO Stock Holding History

Cullen/Frost Bankers’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-83	Closed	-$27K	–	1211
2020 Q2	$27K	Buy	+83	New	+$13.3K	﹤0.01%	759

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Cullen/Frost Bankers's INO Position: Q3 2020 in Review

Cullen/Frost Bankers sold out of Inovio Pharmaceuticals (INO) in Q3 2020, closing a stake of 83 shares — an estimated $27K sold.

Cullen/Frost Bankers first reported a position in INO in Q2 2020 and held it in 1 quarter. The position peaked at $27K in Q2 2020. 212 funds tracked by Wall St. Rank hold INO as of Q3 2020.

Cullen/Frost Bankers reported no remaining Inovio Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Cullen/Frost Bankers sold 83 Inovio Pharmaceuticals shares in Q3 2020, an estimated $27K.
Cullen/Frost Bankers first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 1 quarter.
Cullen/Frost Bankers's Inovio Pharmaceuticals position peaked at $27K in Q2 2020.
212 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2020.

Based on Cullen/Frost Bankers's 13F filing for Q3 2020, filed 5 Nov 2020.